Research library

A

grade

CagriSema shows significant improvements in HbA1c and body weight compared to placebo, but its advantages over semaglutide are less clear, particularly for HbA1c.

-1.87 percentage points HbA1c reduction vs placebo (95% CrI, -2.08 to -1.62)

summary

C

grade

CagriSema can induce weight loss in rats by reducing energy intake, but weight regain occurs rapidly after treatment stops, suggesting ongoing therapy may be necessary.

CS reduced energy intake (EI) and preserved total energy expenditure (EE), explaining 86% and 14% of weight loss efficacy respectively.

summary

A

grade

The REDEFINE 3 trial is designed to assess the cardiovascular safety and efficacy of CagriSema in a high-risk population with established cardiovascular disease and excess adiposity.

7076 adults randomized between 1/2023-12/2024.

summary

A

grade

Coagonists, including cagrilintide, may reduce obesity-associated cancer risk, but further research is needed to confirm these findings.

Coagonists RR=0.43, 95% CI: 0.19 to 0.97

summary

A

grade

Semaglutide and tirzepatide appear most effective for weight loss, but adverse events are a concern. Direct comparisons between treatments remain limited.

112,511 participants across 69 studies.

summary

A

grade

CagriSema significantly enhances weight loss compared to semaglutide, cagrilintide, and placebo, with a favorable safety profile, but long-term effects need further study.

MD = -13.99 kg vs placebo; 95% CI = -18.38 to -9.61; p < 0.00001

summary

B

grade

Semaglutide shows promise in reducing adolescent obesity, but more research is needed on newer treatments and long-term safety.

Semaglutide reduces body mass index by 16.1%.

summary

A

grade

Cagrilintide and CagriSema show promise for weight loss and cardiometabolic improvements in obesity, but further research is needed to confirm long-term benefits and safety.

-6.08% body weight, -5.89 kg with Cagrilintide monotherapy

summary

D

grade

Amylin-based therapies like cagrilintide offer a promising approach to obesity treatment, but understanding their tolerability is key to enhancing clinical utility.

summary

A

grade

The combination of zalfermin and semaglutide did not significantly improve liver fibrosis compared to placebo in this study, while semaglutide alone showed a nominally significant effect.

24 [24%] of 99 participants in the zalfermin 30 mg plus semaglutide 2·4 mg group improved in liver fibrosis vs 16 [16%] of 100 participants in the placebo group; p=0·19.

summary

C

grade

Distinct brain regions mediate the effects of GIPR agonism and antagonism on appetite and weight loss in mice, but the implications for human treatment remain unclear.

Not reported in abstract.

summary

A

grade

CagriSema showed a higher percentage of participants achieving BMI and WHtR targets compared to other treatments, but the clinical significance of these findings requires further investigation.

30.3% achieved BMI < 27 kg/m² and WHtR < 0.53 with CagriSema at week 68.

summary

D

grade

Not reported in abstract.

summary

A

grade

Cagrilintide-semaglutide (2.4 mg each) demonstrated a statistically significant greater reduction in HbA1c compared to semaglutide alone in people with type 2 diabetes.

Mean HbA1c change was significantly greater with cagrilintide-semaglutide (2.4 mg each) versus semaglutide 2.4 mg (-1.91 percentage points vs -1.75 percentage points; p=0.0035).

summary

A

grade

Cagrilintide-semaglutide showed significant reductions in HbA1c and body weight compared to placebo in adults with type 2 diabetes inadequately controlled by diet and exercise.

-1.7 percentage points (95% CI -2.0 to -1.3; p<0.0001) treatment difference for cagrilintide-semaglutide (2.4 mg each) vs placebo.

summary

D

grade

The abstract is not available, preventing any conclusions about the study's findings or implications.

summary

A

grade

The paper suggests that semaglutide represents a significant advancement in obesity treatment, but specific outcomes are not detailed.

–14.9% weight loss vs placebo at 68 wk, n=1961, p<0.001

summary

A

grade

Cagrisema may lead to greater weight loss compared to semaglutide alone, but the clinical relevance of cagrilintide's effects compared to semaglutide/liraglutide is uncertain.

MD -9.07% weight loss at 20-32 weeks with Cagrisema vs semaglutide, 95%CI: -11.91, -6.23; p < 0.00001; I2 = 96%

summary

D

grade

Most studies on anti-obesity medications in Arab countries are observational, with a focus on older drugs like liraglutide, and gastrointestinal side effects were reported in 32.2% of patients.

32.2% of patients reported gastrointestinal side effects.

summary

D

grade

Semaglutide has shown promise in managing type 2 diabetes and obesity, with significant weight loss and glycemic control observed in clinical trials. However, further research is needed to confirm these findings across broader populations.

Not reported in abstract.

summary

D

grade

High dose CagriSema led to a significant weight loss of -17.18% compared to placebo, but findings are based on low-certainty data and require further validation.

-17.18% body weight change with high dose CagriSema vs placebo

summary

C

grade

Not reported in abstract.

Cagrilintide (AM833) had an EC50 value of 0.5 nM for receptor activation.

summary